Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medical Devices: Humanitarian Use Devices, 82301-82302 [2011-33551]
Download as PDF
Federal Register / Vol. 76, No. 251 / Friday, December 30, 2011 / Notices
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, (301)
796–7651,
Juanmanuel.vilela@fda.hhs.gov.
Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology. This document
solicits comments on certain labeling
requirements for blood and blood
components, including Source Plasma,
finalized as part of a rule FDA is
publishing elsewhere in this Federal
Register entitled ‘‘Revisions to Labeling
Requirements for Blood and Blood
Components, Including Source Plasma.’’
SUPPLEMENTARY INFORMATION:
srobinson on DSK4SPTVN1PROD with NOTICES
Revisions to Labeling Requirements for
Blood and Blood Components,
Including Source Plasma—(OMB
Control Number 0910–NEW)
FDA is finalizing the labeling
requirements for blood or blood
components intended for use in
transfusion or for further manufacture
pursuant to the provisions of the Public
Health Service Act (PHS Act) (42 U.S.C.
262–264), and the drugs, devices, and
general administrative provisions of the
VerDate Mar<15>2010
19:02 Dec 29, 2011
Jkt 226001
Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 321, 331, 351–353, 355, 360,
360j, 371, and 374). Under these
provisions of the PHS Act and the
Federal Food, Drug, and Cosmetic Act,
we have the authority to issue and
enforce regulations designed to ensure
that biological products are safe, pure,
potent, and properly labeled, and to
prevent the introduction, transmission,
and spread of communicable disease.
Under this rulemaking, FDA is
consolidating the regulations related to
labeling blood and blood components.
Regulations for labeling of blood and
blood components will be consolidated
into § 606.121 (Container label) (21 CFR
606.121) and 21 CFR 606.122 (Circular
of information). This notice solicits
comments on the information collection
associated with § 606.121(c)(11) (21 CFR
606.121(c)(11)) which requires that if
the product is intended for further
manufacturing use, a statement listing
the results of all the tests for
communicable disease agents required
under § 610.40 (21 CFR 610.40) for
which the donation has been tested and
found negative must be on the container
label; except that the label for Source
Plasma is not required to list the
negative results of serological syphilis
testing under § 610.40(i) (21 CFR
610.40(i)) and § 640.65(b) (21 CFR
640.65(b)). In addition, this notice also
solicits comments on the information
collection associated with
§ 606.121(e)(2)(i) (21 CFR
606.121(e)(2)(i)) which requires that the
product labels of certain red blood cells
must include the type of additive
solution with which the product was
prepared.
The Agency believes the rule
amendments and the information
collection provisions under
§ 606.121(c)(11) and § 606.121(e)(2)(i) in
the final rule are part of usual and
customary business practice and do not
create any new burden for respondent.
The collection of information
requirements under §§ 606.121 and
606.122 are approved under OMB
control number 0910–0116; and those in
21 CFR 640.70 have been approved
under OMB control number 0910–0338.
Under 5 CFR 1320.3(b)(2), the time,
effort, and financial resources necessary
to comply with a collection of
information are excluded from the
burden estimate if the reporting,
recordkeeping, or disclosure activities
needed to comply are usual and
customary because they would occur in
the normal course of activities.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
82301
Dated: December 22, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–33555 Filed 12–29–11; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0619]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Medical Devices:
Humanitarian Use Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by January 30,
2012.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax:
(202) 395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0332. Also
include the FDA docket number found
in brackets in the heading of this
document.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Daniel Gittleson, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
5156, Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Medical Devices: Humanitarian Use
Devices—(OMB Control Number 0910–
0332)—Extension
This collection of information
implements the humanitarian use
device (HUD) provision of section
520(m) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C.
360j(m)) and subpart H, part 814 (21
CFR part 814). Under section 520(m) of
E:\FR\FM\30DEN1.SGM
30DEN1
82302
Federal Register / Vol. 76, No. 251 / Friday, December 30, 2011 / Notices
the FD&C Act, FDA is authorized to
exempt an HUD from the effectiveness
requirements of sections 514 and 515 of
the FD&C Act (21 U.S.C. 360d and 360e)
provided that the device: (1) Is used to
treat or diagnose a disease or condition
that affects fewer than 4,000 individuals
in the United States; (2) would not be
available to a person with such a disease
or condition unless an exemption is
granted because there is no comparable
device other than another HUD
approved under this exemption that is
available to treat or diagnose the disease
or condition; and (3) will not expose
patients to an unreasonable or
significant risk of illness or injury with
the probable benefit to health from
using the device outweighing the risk of
injury or illness from its use. This takes
into account the probable risks and
benefits of currently available devices or
alternative forms of treatment.
The information collected will assist
FDA in making determinations on the
following: (1) Whether to grant HUD
designation of a medical device; (2)
exempt an HUD from the effectiveness
requirements under sections 514 and
515 of the FD&C Act, provided that the
device meets requirements set forth
under section 520(m) of the FD&C Act;
and (3) whether to grant marketing
approval(s) for the HUD. Failure to
collect this information would prevent
FDA from making a determination on
the factors listed previously in this
document. Further, the collected
information would also enable FDA to
determine whether the holder of an
HUD is in compliance with the HUD
provisions under section 520(m) of the
FD&C Act.
The number of respondents in tables
1 and 2 of this document are an average
from data for the previous 3 years, i.e.,
fiscal years 2008 to 2010. The number
of annual reports submitted under
section 814.126(b)(1) in table 1 reflects
43 respondents with approved HUD
applications. Likewise, under section
814.126(b)(2) in table 2, the number of
recordkeepers is 43.
In the Federal Register of September
7, 2011 (76 FR 55394), FDA published
a 60-day notice requesting public
comment on the proposed collection of
information. No comments were
received.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
21 CFR Section
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
814.102 ................................................................................
814.104 ................................................................................
814.106 ................................................................................
814.108 ................................................................................
814.116(e)(3) .......................................................................
814.124(a) ............................................................................
814.124(b) ............................................................................
814.126(b)(1) .......................................................................
17
5
5
47
3
22
12
43
1
1
5
1
1
1
1
1
17
5
25
47
3
22
12
43
40
320
50
80
1
1
2
120
680
1,600
1,250
3,760
3
22
24
5,160
Total ..............................................................................
........................
........................
........................
........................
12,499
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1
Number of
recordkeeper
21 CFR Section
814.126(b)(2) .......................................................................
1 There
43
Total annual
records
1
43
Average
burden per
recordkeeping
2
Total hours
86
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: December 27, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011–33551 Filed 12–29–11; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–P–0555]
BILLING CODE 4160–01–P
srobinson on DSK4SPTVN1PROD with NOTICES
Number of
records per
recordkeeper
Determination That HYCODAN
(Hydrocodone Bitartrate and
Homatropine Methylbromide) Tablets,
5 Milligrams/1.5 Milligrams, and
HYCODAN (Hydrocodone Bitartrate
and Homatropine Methylbromide) Oral
Solution, 5 Milligrams/5 Milliliters and
1.5 Milligrams/5 Milliliters, Were Not
Withdrawn From Sale for Reasons of
Safety or Effectiveness
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
VerDate Mar<15>2010
19:02 Dec 29, 2011
Jkt 226001
PO 00000
Notice.
Frm 00035
Fmt 4703
Sfmt 4703
The Food and Drug
Administration (FDA) has determined
that HYCODAN (hydrocodone bitartrate
and homatropine methylbromide)
tablets, 5 milligrams (mg)/1.5 mg, and
HYCODAN (hydrocodone bitartrate and
homatropine methylbromide) oral
solution, 5 mg/5 milliliters (mL) and 1.5
mg/5 mL, were not withdrawn from sale
for reasons of safety or effectiveness.
This determination will allow FDA to
approve abbreviated new drug
applications (ANDAs) for hydrocodone
bitartrate and homatropine
methylbromide tablets, 5 mg/1.5 mg,
and HYCODAN (hydrocodone bitartrate
and homatropine methylbromide) oral
solution, 5 mg/5 mL and 1.5 mg/5 mL,
if all other legal and regulatory
requirements are met.
SUMMARY:
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 76, Number 251 (Friday, December 30, 2011)]
[Notices]
[Pages 82301-82302]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33551]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0619]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Medical Devices:
Humanitarian Use Devices
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by January
30, 2012.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
Fax: (202) 395-7285, or emailed to oira_submission@omb.eop.gov. All
comments should be identified with the OMB control number 0910-0332.
Also include the FDA docket number found in brackets in the heading of
this document.
FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, (301) 796-5156,
Daniel.Gittleson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Medical Devices: Humanitarian Use Devices--(OMB Control Number 0910-
0332)--Extension
This collection of information implements the humanitarian use
device (HUD) provision of section 520(m) of the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) (21 U.S.C. 360j(m)) and subpart H, part 814
(21 CFR part 814). Under section 520(m) of
[[Page 82302]]
the FD&C Act, FDA is authorized to exempt an HUD from the effectiveness
requirements of sections 514 and 515 of the FD&C Act (21 U.S.C. 360d
and 360e) provided that the device: (1) Is used to treat or diagnose a
disease or condition that affects fewer than 4,000 individuals in the
United States; (2) would not be available to a person with such a
disease or condition unless an exemption is granted because there is no
comparable device other than another HUD approved under this exemption
that is available to treat or diagnose the disease or condition; and
(3) will not expose patients to an unreasonable or significant risk of
illness or injury with the probable benefit to health from using the
device outweighing the risk of injury or illness from its use. This
takes into account the probable risks and benefits of currently
available devices or alternative forms of treatment.
The information collected will assist FDA in making determinations
on the following: (1) Whether to grant HUD designation of a medical
device; (2) exempt an HUD from the effectiveness requirements under
sections 514 and 515 of the FD&C Act, provided that the device meets
requirements set forth under section 520(m) of the FD&C Act; and (3)
whether to grant marketing approval(s) for the HUD. Failure to collect
this information would prevent FDA from making a determination on the
factors listed previously in this document. Further, the collected
information would also enable FDA to determine whether the holder of an
HUD is in compliance with the HUD provisions under section 520(m) of
the FD&C Act.
The number of respondents in tables 1 and 2 of this document are an
average from data for the previous 3 years, i.e., fiscal years 2008 to
2010. The number of annual reports submitted under section
814.126(b)(1) in table 1 reflects 43 respondents with approved HUD
applications. Likewise, under section 814.126(b)(2) in table 2, the
number of recordkeepers is 43.
In the Federal Register of September 7, 2011 (76 FR 55394), FDA
published a 60-day notice requesting public comment on the proposed
collection of information. No comments were received.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR Section Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
814.102......................... 17 1 17 40 680
814.104......................... 5 1 5 320 1,600
814.106......................... 5 5 25 50 1,250
814.108......................... 47 1 47 80 3,760
814.116(e)(3)................... 3 1 3 1 3
814.124(a)...................... 22 1 22 1 22
814.124(b)...................... 12 1 12 2 24
814.126(b)(1)................... 43 1 43 120 5,160
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 12,499
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Table 2--Estimated Annual Recordkeeping Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR Section Number of records per Total annual per Total hours
recordkeeper recordkeeper records recordkeeping
----------------------------------------------------------------------------------------------------------------
814.126(b)(2)................... 43 1 43 2 86
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Dated: December 27, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-33551 Filed 12-29-11; 8:45 am]
BILLING CODE 4160-01-P